Zealand Pharma: partner starts two phase I studies.

(CercleFinance.com) - Zealand Pharma said that its German partner Boehringer Ingelheim has started two Phase 1 trials on two novel treatments for obesity and/or diabetes.


The first deals with a glucagon/GLP-1 agonist that has the potential for once-weekly administration for the treatment of obesity and/or type-2 diabetes and the second with a novel differentiated long-acting amylin analog for the treatment of obesity and/or diabetes.

Both compounds were invented through Zealand and Boehringer Ingelheim research collaboration.

After this initiation, Zealand to receive a 4 million euros (30 million Danish kroner) milestone payment.

Results on both compounds are expected in late 2018.

Copyright (c) 2017 CercleFinance.com. All rights reserved.